Could cause temporary or reversible harm; serious harm is unlikely.
Presence of foreign substance: Presence of stainless steel particulates in tablets.
| Brand name | JANUMET |
| Generic name | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE |
| Distributed by / for | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA, by Patheon Puerto Rico, Inc. Manati, Puerto Rico, 00674 Bottle (NDC 0006-0575-02), Carton (NDC 0006-0575-03) |
| NDC | 0006-0575-02 |
| Full product label | Janumet (sitagliptin and metformin HCl) tablets, 50 mg/500 mg, 14-count bottle, packaged as 2 bottles per carton , Sample-Not For Sale, Rx Only, Manufactured for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA, by Patheon Puerto Rico, Inc. Manati, Puerto Rico, 00674 Bottle (NDC 0006-0575-02), Carton (NDC 0006-0575-03) |
| Recalling firm | MERCK SHARP & DOHME CORP |
| Distribution | Nationwide in the USA |
| Quantity | 3600 cartons |
| Recall initiated | 2022-03-31 |
| Report date | 2022-04-13 |
| Recall completed | 2023-08-15 |
| Recall number | D-0746-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Whitehouse Station NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗